GuidelineBlood advances2025
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients.
Guideline in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Efficacy and safety of anticoagulation for pediatric cerebral sinovenous thrombosis: systematic review and meta-analysis.Research and practice in thrombosis and haemostasis · 2026Pooled it
- Incidence of neonatal venous thromboembolism: a systematic review and meta-analysis of the literature.Research and practice in thrombosis and haemostasis · 2026Pooled it
- Epidemiological characteristics of pulmonary thromboembolism in children: a systematic review and meta-analysis.BMJ open · 2026Pooled it
- Pooled it
- Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis.Blood advances · 2025Pooled it
- Safety and efficacy of endovascular treatment in symptomatic pediatric cerebral venous sinus thrombosis.Neuroradiology · 2026Article
- Venous Thromboembolism in Neonates, Children, and Adolescents: A Comprehensive Narrative Review of Risk Factors, Diagnosis, Treatment, and Prevention.Medicina (Kaunas, Lithuania) · 2026Review
- Catheter Thrombectomy of Massive Pulmonary Embolism Secondary to Spongostan Embolisation: A Case Report.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
- [Clinical characteristics, diagnosis, and treatment of 40 cases of venous thrombotic disease in children at a single center].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Neonatal Thromboembolic Disease: Clinical Spectrum and Emerging Evidence for Diagnostic and Therapeutic Strategies Addressing Unmet Needs.Journal of clinical medicine · 2026Review
- Evaluation of Enoxaparin Dosing in Infants Greater Than 2 to 6 Months of Age, a Pre and Post Quasi Experiment.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Pediatric venous thromboembolism: an illustrated review.Research and practice in thrombosis and haemostasis · 2026Review
- Current practices of index hospitalization anticoagulant use in pediatric patients with acute myeloid leukemia.Blood vessels, thrombosis & hemostasis · 2026Article
- Extended-phase anticoagulation for pediatric venous thromboembolism after EINSTEIN Jr.Translational pediatrics · 2026Article
- Renal Vein Thrombosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Inpatient Characteristics and Outcomes of Venous Thromboembolism Among Children and Adolescents.JAMA network open · 2026Article
- Heparin Resistance - A Reality or Fallacy.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Rivaroxaban for extended anticoagulation of pediatric venous thromboembolism.Translational pediatrics · 2026Article
- Rare pediatric multi-system thrombosis post-COVID-19: a three-year follow-up case report and narrative review on rivaroxaban for long-term management.Orphanet journal of rare diseases · 2026Review
- Early clot resolution in neonates: time to rethink duration of anticoagulation in neonatal catheter-related venous thromboembolism?Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe American Society of Hematology (ASH) guidelines on treatment of pediatric venous thromboembolism (VTE) were published in 2018. In the last 6 years, there has been a 10-fold increase in the number of children involved in VTE treatment trials.
objectiveThe ASH Committee on Quality and Guidelines agreed to update the pediatric guidelines in conjunction with the International Society on Thrombosis and Haemostasis (ISTH). These ASH/ISTH evidence-based guidelines are intended to support patients, clinicians, and other health care professionals in the management of pediatric patients with VTE.
methodsASH/ISTH formed a multidisciplinary guideline panel to minimize potential bias from conflicts of interest. An unconflicted patient representative was not identified. The University of Kansas Health System supported the guideline development process, updating or performing systematic evidence reviews up to 2024. The panel focused specifically on the 2018 questions for which there was the greatest amount of interim data. The panel used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment.
resultsThe panel agreed on 20 recommendations and also provided implementation guidance on the optimal use of anticoagulants in pediatric patients. Key recommendations of these guidelines include the role of DOACs in the treatment of a variety of pediatric VTEs.
conclusionsFurther research is required. Key priorities are understanding the natural history of clinically unsuspected thrombosis across a range of patient subpopulations and obtaining real-world data on the use of DOACs in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.